Free Trial

Medtronic (MDT) Stock Forecast & Price Target

Medtronic logo
$81.03 +1.04 (+1.30%)
(As of 05:45 PM ET)

Medtronic - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
1
Hold
9
Buy
7

Based on 17 Wall Street analysts who have issued ratings for Medtronic in the last 12 months, the stock has a consensus rating of "Hold." Out of the 17 analysts, 1 has given a sell rating, 9 have given a hold rating, 6 have given a buy rating, and 1 has given a strong buy rating for MDT.

Consensus Price Target

$95.00
17.24% Upside
According to the 17 analysts' twelve-month price targets for Medtronic, the average price target is $95.00. The highest price target for MDT is $109.00, while the lowest price target for MDT is $83.00. The average price target represents a forecasted upside of 17.24% from the current price of $81.03.
Get the Latest News and Ratings for MDT and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Medtronic and its competitors.

Sign Up

MDT Analyst Ratings Over Time

TypeCurrent Forecast
12/21/23 to 12/20/24
1 Month Ago
11/21/23 to 11/20/24
3 Months Ago
9/22/23 to 9/21/24
1 Year Ago
12/21/22 to 12/21/23
Strong Buy
1 Strong Buy rating(s)
1 Strong Buy rating(s)
1 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
6 Buy rating(s)
7 Buy rating(s)
4 Buy rating(s)
6 Buy rating(s)
Hold
9 Hold rating(s)
9 Hold rating(s)
9 Hold rating(s)
4 Hold rating(s)
Sell
1 Sell rating(s)
1 Sell rating(s)
1 Sell rating(s)
1 Sell rating(s)
Consensus Price Target$95.00$95.19$92.92$93.33
Forecasted Upside17.24% Upside13.17% Upside4.01% Upside13.88% Upside
Consensus Rating
Hold
Hold
Hold
Hold

MDT Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

MDT Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Medtronic Stock vs. The Competition

TypeMedtronicMedical CompaniesS&P 500
Consensus Rating Score
2.41
2.81
2.51
Consensus RatingHoldModerate BuyModerate Buy
Predicted Upside17.24% Upside25,183.93% Upside14.32% Upside
News Sentiment Rating
Positive News

See Recent MDT News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
12/18/2024Truist Financial
2 of 5 stars
 Lower TargetHold ➝ Hold$93.00 ➝ $89.00+9.44%
11/26/2024Barclays
3 of 5 stars
 Boost TargetOverweight ➝ Overweight$105.00 ➝ $109.00+27.11%
11/20/2024Sanford C. Bernstein
3 of 5 stars
 Boost TargetOutperform ➝ Outperform$96.00 ➝ $97.00+15.68%
11/20/2024Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight ➝ Overweight$106.00 ➝ $98.00+13.95%
11/20/2024Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetNeutral ➝ Neutral$96.00 ➝ $93.00+9.40%
11/18/2024Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingHold
11/15/2024JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetNeutral ➝ Neutral$99.00 ➝ $96.00+9.84%
10/10/2024Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
S. Singh
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeSector Perform ➝ Outperform$98.00 ➝ $105.00+18.85%
10/1/2024Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetNeutral ➝ Neutral$85.00 ➝ $92.00+2.76%
10/1/2024Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform ➝ Outperform$100.00 ➝ $104.00+16.16%
8/23/2024Daiwa America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
R. Department
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
8/21/2024Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetNeutral ➝ Neutral$85.00 ➝ $90.00+4.41%
8/21/2024Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetHold ➝ Hold$85.00 ➝ $87.00+1.90%
8/21/2024Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetMarket Perform ➝ Market Perform$92.00 ➝ $94.00+10.10%
8/15/2024UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
D. Antalffy
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeSell ➝ Neutral$76.00 ➝ $90.00+10.12%
5/30/2024The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageSell$83.00+1.84%
2/21/2024Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$95.00 ➝ $98.00+14.71%
11/22/2023Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight ➝ Overweight$104.00 ➝ $98.00+24.68%
6/30/202322nd Century Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingInitiates
6/30/2023CL King
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$106.00+22.16%
2/22/2023Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$80.00 ➝ $87.00+1.12%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Friday at 09:38 PM ET.


Should I Buy Medtronic Stock? MDT Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Thursday, December 12, 2024. Please send any questions or comments about these Medtronic pros and cons to contact@marketbeat.com.

Medtronic
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in Medtronic plc:

  • Medtronic plc recently reported a quarterly earnings per share (EPS) of $1.26, exceeding analysts' expectations of $1.25, indicating strong financial performance and effective management.
  • The company has a solid revenue stream, with reported revenue of $8.40 billion for the latest quarter, surpassing estimates and reflecting a year-over-year growth of 5.2%.
  • Medtronic plc has a current stock price of $84.01, which is below the consensus target price of $95.27, suggesting potential for price appreciation.
  • The company offers a quarterly dividend of $0.70, translating to an annualized dividend yield of 3.33%, providing a steady income stream for investors.
  • Analysts have a consensus rating of "Hold" for Medtronic plc, with a mix of buy and hold ratings, indicating a generally favorable outlook among market experts.

Medtronic
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in Medtronic plc for these reasons:

  • Despite recent positive earnings, the stock has experienced volatility, with a 52-week low of $75.96, which may raise concerns about its stability.
  • The company's debt-to-equity ratio stands at 0.51, which, while manageable, indicates that Medtronic plc is utilizing debt to finance its operations, potentially increasing financial risk.
  • Analysts have issued a sell rating from one analyst, suggesting that there are concerns about the stock's future performance.
  • The stock's price-to-earnings (P/E) ratio of 25.69 is relatively high, which may indicate that the stock is overvalued compared to its earnings, potentially deterring value-focused investors.
  • Market sentiment can be influenced by broader economic conditions, and any downturn could negatively impact Medtronic plc's stock performance.

MDT Forecast - Frequently Asked Questions

According to the research reports of 17 Wall Street equities research analysts, the average twelve-month stock price forecast for Medtronic is $95.00, with a high forecast of $109.00 and a low forecast of $83.00.

17 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Medtronic in the last year. There is currently 1 sell rating, 9 hold ratings, 6 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" MDT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MDT, but not buy additional shares or sell existing shares.

According to analysts, Medtronic's stock has a predicted upside of 17.24% based on their 12-month stock forecasts.

Over the previous 90 days, Medtronic's stock had 1 upgrade by analysts.

Analysts like Medtronic less than other "medical" companies. The consensus rating for Medtronic is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how MDT compares to other companies.


This page (NYSE:MDT) was last updated on 12/20/2024 by MarketBeat.com Staff
From Our Partners